Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors  Pradnya Chopade, Luke P. Akard  Clinical Lymphoma, Myeloma and Leukemia  Volume 18, Issue 11, Pages 710-723 (November 2018) DOI: 10.1016/j.clml.2018.06.029 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Response Milestones for Tyrosine Kinase Inhibitor (TKI) Therapy and Associated Clinical Considerations per 2018 National Comprehensive Cancer Network (NCCN) Guidelines23,a Abbreviations: HCT, hematopoietic cell transplantation; IS, International Scale. aAdapted, with permission, from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Myeloid Leukemia. V.4.2018. ©2018 National Comprehensive Cancer Network, Inc. All rights reserved. © 2018 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. bPatients with BCR-ABL1IS only slightly > 10% at 3 months and/or with a steep decline from baseline can achieve < 10% at 6 months and have generally favorable outcomes. Therefore, it is important to interpret the value at 3 months in this context before making drastic changes to the treatment strategy. cAchievement of response milestones must be interpreted within the clinical context. Patients with > 50% reduction compared with baseline or minimally greater than the 10% cutoff can continue the same dose of dasatinib, nilotinib, or bosutinib for another 3 months. dDiscontinuation of TKI therapy with careful monitoring is feasible for selected patients. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 710-723DOI: (10.1016/j.clml.2018.06.029) Copyright © 2018 The Authors Terms and Conditions